NCT00056459

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,168 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment

Conditions

• Colorectal Neoplasms
• Colonic Neoplasms
• Rectal Neoplasms

Interventions

Type	Name	Description
DRUG	Vatalanib

Timeline

• Start date: 2003-02-01
• Primary completion: 2007-01-01
• First posted: 2003-03-14
• Last updated: 2020-02-10

Locations

223 sites across 19 countries: United States, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Portugal, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom